These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Construction and Immunological Evaluation of an Adenoviral Vector-Based Vaccine Candidate for Lassa Fever. Wang M; Li R; Li Y; Yu C; Chi X; Wu S; Liu S; Xu J; Chen W Viruses; 2021 Mar; 13(3):. PubMed ID: 33804206 [TBL] [Abstract][Full Text] [Related]
23. Detection of Lassa virus in wild rodent feces: Implications for Lassa fever burden within households in the endemic region of Faranah, Guinea. Wood R; Bangura U; Mariën J; Douno M; Fichet-Calvet E One Health; 2021 Dec; 13():100317. PubMed ID: 34522759 [TBL] [Abstract][Full Text] [Related]
24. Comparative Evaluation of Standard RT-PCR Assays and Commercial Real-Time RT-PCR Kits for Detection of Lassa Virus. Luo XL; Zhang XD; Li BJ; Qin T; Cao ZJ; Fan QJ; Yang J; Jin D; Lu S; Zheng YY; Xu XF; Pu J; Xu J Microbiol Spectr; 2023 Mar; 11(2):e0501122. PubMed ID: 36976009 [TBL] [Abstract][Full Text] [Related]
25. Lassa Virus Cell Entry via Dystroglycan Involves an Unusual Pathway of Macropinocytosis. Oppliger J; Torriani G; Herrador A; Kunz S J Virol; 2016 Jul; 90(14):6412-6429. PubMed ID: 27147735 [TBL] [Abstract][Full Text] [Related]
26. Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs. Maruyama J; Mateer EJ; Manning JT; Sattler R; Seregin AV; Bukreyeva N; Jones FR; Balint JP; Gabitzsch ES; Huang C; Paessler S Vaccine; 2019 Oct; 37(45):6824-6831. PubMed ID: 31561999 [TBL] [Abstract][Full Text] [Related]
27. Understanding Immune Responses to Lassa Virus Infection and to Its Candidate Vaccines. Murphy H; Ly H Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298533 [TBL] [Abstract][Full Text] [Related]
28. Development of an RT-LAMP assay for the detection of Lassa viruses in southeast and south-central Nigeria. Pemba CM; Kurosaki Y; Yoshikawa R; Oloniniyi OK; Urata S; Sueyoshi M; Zadeh VR; Nwafor I; Iroezindu MO; Ajayi NA; Chukwubike CM; Chika-Igwenyi NM; Ndu AC; Nwidi DU; Maehira Y; Unigwe US; Ojide CK; Onwe EO; Yasuda J J Virol Methods; 2019 Jul; 269():30-37. PubMed ID: 30974179 [TBL] [Abstract][Full Text] [Related]
29. Lassa virus diversity and feasibility for universal prophylactic vaccine. Lukashevich IS; Paessler S; de la Torre JC F1000Res; 2019; 8():. PubMed ID: 30774934 [TBL] [Abstract][Full Text] [Related]
30. Geographic distribution and genetic characterization of Lassa virus in sub-Saharan Mali. Safronetz D; Sogoba N; Lopez JE; Maiga O; Dahlstrom E; Zivcec M; Feldmann F; Haddock E; Fischer RJ; Anderson JM; Munster VJ; Branco L; Garry R; Porcella SF; Schwan TG; Feldmann H PLoS Negl Trop Dis; 2013; 7(12):e2582. PubMed ID: 24340119 [TBL] [Abstract][Full Text] [Related]
31. Lassa Fever Natural History and Clinical Management. Grant DS; Samuels RJ; Garry RF; Schieffelin JS Curr Top Microbiol Immunol; 2023; 440():165-192. PubMed ID: 37106159 [TBL] [Abstract][Full Text] [Related]
32. Immunogenicity of a protective intradermal DNA vaccine against lassa virus in cynomolgus macaques. Jiang J; Banglore P; Cashman KA; Schmaljohn CS; Schultheis K; Pugh H; Nguyen J; Humeau LM; Broderick KE; Ramos SJ Hum Vaccin Immunother; 2019; 15(9):2066-2074. PubMed ID: 31071008 [TBL] [Abstract][Full Text] [Related]